A new algorithm unveils CRISPR ‘treasure trove’
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Category: biotechnology
STAT+: With biotech in a slump, the industry’s job market is upside down
After earning her doctorate in cell biology at the University of Pennsylvania in June, Sierra…
STAT+: With new trial data, a blockbuster therapy from Sanofi, Regeneron could find an even bigger market
LONDON — The inflammation-targeting therapy Dupixent succeeded in a Phase 3 trial in patients with…
Medtronic isn’t afraid of Wegovy’s potential to disrupt
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Evelo Biosciences, a microbiome company launched by Flagship, shuts down
Evelo Biosciences, a startup hoping to use the trillions of microbes in and on the…
Bayer’s new CEO was dealt a duo of ‘clearing events.’ Tough choices lie ahead
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Flagship Pioneering launches Quotient, a new biotech, in two countries
Flagship Pioneering, the venture capital firm behind Moderna, on Tuesday unveiled a new biotech called…
STAT+: Mixed study results for MorphoSys blood-cancer drug raise questions about approval
LONDON — An experimental blood cancer drug from MorphoSys hit its primary target in a…
Merck cough drug doesn’t pass panel scrutiny
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: What Eli Lilly’s Zepbound reveals about the intricate process of naming drugs today
Whether you’re a fan of the drug name Zepbound or, like one X user, think…
The return of biotech’s “bump factor” amid an economic downturn
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Even as Wegovy rides high, interest surges in weight loss drugs that preserve muscle
Have you ever seen a mouse with a set of muscles more appropriate for a…
STAT+: FDA’s Janet Woodcock to retire early next year
WASHINGTON — Principal Deputy FDA Commissioner Janet Woodcock will retire early next year from the…
Key questions (and answers) about the historic approval of a CRISPR-based medicine
History just happened. For the first time, a regulator has cleared a treatment using CRISPR,…
Listen: A CRISPR milestone, algorithms amok, & biotech mixology
Who polices algorithms? How would you name the first approved CRISPR medicine? And what pairs…
How do we know Alzheimer’s drugs ‘work’?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Bristol wins U.S. approval for lung cancer drug targeting rare genetic mutation
The Food and Drug Administration on Wednesday approved a new treatment for people with non-small…
STAT+: U.K. approves world’s first CRISPR-based medicine, giving greenlight to therapy for sickle cell, thalassemia
LONDON — Regulators in the U.K. on Thursday approved a CRISPR-based medicine to treat both…
STAT+: After four patients died of gene therapy, Astellas sees possible explanation — and a way forward
A gene therapy study, halted when four children with a rare neuromuscular disorder died after…
STAT+: FDA’s latest reorganization puts a new emphasis on its investigations
WASHINGTON — There’s about to be a new acronym in town. The Food and Drug…
The apparently strong correlation between biotech stocks and the price of eggs, explained
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: To get things done fast at FDA: ‘Don’t tell anybody,’ cancer chief says
WASHINGTON — The Food and Drug Administration’s top cancer drug regulator doesn’t always ask for…
STAT+: Life scientists’ flight to biotech labs stalls important academic research
Step inside Natasha Sheybani’s office at the University of Virginia, where she runs a bioengineering…
STAT+: New NIH head says government has fallen behind pharma on clinical trials
WASHINGTON — The new National Institutes of Health director, Monica Bertagnolli, said it’s a “failure”…
What health policies could hitch a ride on a spending bill?
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and…
Novo Nordisk has its sights on becoming a major player in heart disease
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Eli Lilly’s chief scientist on new obesity drug data, gene editing, and a potential new heart drug
PHILADELPHIA — In a sense, the annual meeting of the American Heart Association wasn’t a…
STAT+: In first test for base editing, Verve’s one-time treatment lowers cholesterol levels in patients
Verve Therapeutics said Sunday that the first 10 people to receive a one-time treatment powered…
STAT+: Vacancy rate in Boston-area lab space climbs to 10-year high
As Massachusetts biotech companies slash jobs and face dwindling investments, it appears that the long-red-hot real…
The first vaccine for the increasingly prevalent chikungunya virus is here
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Listen: Lilly’s obesity drug, the power of radiation, & a biotech implosion
What’s a radiopharmaceutical? What does it mean to be Zepbound? And who’s to blame for…
Eli Lilly tries a rare tactic: competing on price
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Senate panel clears PBM reforms, safety-net hospital payments
WASHINGTON — A prominent Senate panel on Wednesday passed a new package of health policy…
Why do some CAR-T cancer patients have severe complications? Data points to latent virus
The therapy, an infusion of CAR-T cells designed to kill the lymphoma, was going well….
BioMarin’s new CEO inherits a profitable company, a pioneering gene therapy, and a brewing activist challenge
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Biotech incubator Curie.Bio graduates its first startup
Curie.Bio, the new biotech investment firm and incubator launched earlier this year by a group…
STAT+: In the fight against cancer, it’s boom times for radiopharmaceuticals
When Ken Song was getting ready to leave his job as the CEO of a…
Sen. Bernie Sanders moves toward another hearing with pharma CEOs
You’re reading the web edition of D.C. Diagnosis. Sign up here to receive this newsletter in your…
STAT+: Drug shortages and the supply chain are a matter of national security, experts say
WASHINGTON – The pandemic showed how fragile the supply chain can be, and to fix…
Your morning biotech news roundup
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Ventyx stock craters after lackluster mid-stage trial results for psoriasis drug
SAN DIEGO — Ventyx Biosciences reported on Monday that it was ending development of an…
.jpg)
STAT+: Moonlake’s credibility takes another hit with mid-stage study spin job
Moonlake Immunotherapeutics, a Swiss biotech, was buried Monday under an avalanche of its own data…
STAT+: Vertex may face another battle in the U.K. over the value of its cystic fibrosis medicines
Once again, Vertex Pharmaceuticals and a U.K. government agency are at odds over the value…
XBI biotech index rises, giving investors a shred of hope
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Astellas shows enough data for eye treatment to support expanded use, but still lags competitor
Astellas on Saturday presented study results showing an increased treatment effect over time for its…
Shrinking COVID vaccine sales has Moderna course-correcting
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Listen: Decoding biotech hype, the Sarepta saga, & au revoir to a CEO
When is a failure not a failure? Does the FDA have special rules for Sarepta…
Novo Nordisk is concluding research on Wegovy’s impact on osteoarthritis
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: After Sarepta trial failure, families and doctors brace for another debate on Duchenne therapy
To hear Sarepta CEO Doug Ingram tell it, the results Monday afternoon from a large…